Capital Initiative

Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne. The company focuses on developing innovative therapeutic peptides aimed at treating inflammation. Xigen's peptides offer metabolic stability and specificity, allowing for selective delivery to intracellular targets through proprietary carrier molecules. This technology enables healthcare professionals to address a wide range of diseases effectively. The company is led by Dr. Christophe Bonny, a molecular biologist with extensive research experience in intracellular peptides and signaling.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that specializes in the discovery, development, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. The company primarily focuses on allosteric modulators, a novel class of orally available drugs that interact with G-protein coupled receptors, potentially offering advantages over traditional therapeutic approaches. Its lead product candidates include Dipraglurant for treating Parkinson's disease-related dyskinesia and dystonia, ADX71149 for epilepsy and other CNS disorders, and GABAB PAM for addiction. Addex has established a collaboration with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds aimed at addressing various health issues. Founded in 2002, Addex Therapeutics continues to advance its innovative drug discovery platform to improve therapeutic outcomes for patients with neurological conditions.

Dartfish SA specializes in developing video solutions that enable users to capture, analyze, and share video content effectively. Founded in 1998 and headquartered in Fribourg, Switzerland, the company offers a suite of applications and services, including myDartfish, a personal workspace for skill and game analysis, and myDartfish Express, which helps athletes identify areas for improvement. Their platform features myDartfish Smart Cloud for secure video storage and sharing, as well as ProSuite for automatic tracking of video annotations. Dartfish also provides tools for match analysis and data integration, along with Dartfish.tv, a platform for sharing video analysis. By serving diverse markets such as sports, education, healthcare, and industry, Dartfish makes video accessible to coaches, athletes, students, and organizations worldwide. The company operates additional offices across several countries, including the United States, Australia, and various locations in Europe and Asia.